Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoglobulin Replacement Therapy for Preventing Infections After CD19 CAR-T Therapy
NCT05952804Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2024
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in infectious complications, hypogammaglobulinemia, sponsored by Fred Hutchinson Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
infectious complicationshypogammaglobulinemia
Beyond the preview
Go deeper on NCT05952804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952804.